GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH) » Definitions » Revenue

Redhill Biopharma (STU:2RH) Revenue : €5.02 Mil (TTM As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma Revenue?

Redhill Biopharma's revenue for the three months ended in Jun. 2024 was €0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €5.02 Mil. Redhill Biopharma's Revenue per Share for the three months ended in Jun. 2024 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €44.31.

Warning Sign:

Redhill Biopharma Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Redhill Biopharma was -95.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -75.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was -21.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 58.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Redhill Biopharma's highest 3-Year average Revenue per Share Growth Rate was 1000.10% per year. The lowest was -75.80% per year. And the median was 69.65% per year.


Redhill Biopharma Revenue Historical Data

The historical data trend for Redhill Biopharma's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Revenue Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.66 52.90 75.90 58.34 5.99

Redhill Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Jun24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.08 3.36 1.66 - -

Competitive Comparison of Redhill Biopharma's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Revenue distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Revenue falls into.



Redhill Biopharma Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redhill Biopharma  (STU:2RH) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Redhill Biopharma Revenue Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Redhill Biopharma Headlines

No Headlines